VitMode

Liver Cirrhosis: Causes, Symptoms, and Stages of the Disease

Liver cirrhosis is the end stage of many different chronic liver diseases — not just alcohol misuse, though that association still dominates public perception. We explain the real causes of cirrhosis, why the distinction between compensated and decompensated disease is fundamental to prognosis, and which symptoms should prompt urgent medical attention.

MNMichał NowakSeptember 21, 202613 min read
Table of contents

A disease that rarely has just one cause

Liver cirrhosis is a condition in which normal, functional liver tissue is gradually replaced by fibrous (scar) tissue, disrupting the organ's architecture and impairing its function. It isn't a single disease but a shared end stage of many different chronic disease processes unfolding in the liver over years, often decades, before fully developed cirrhosis sets in.

In public perception, liver cirrhosis is still associated almost exclusively with alcohol misuse — and indeed, alcohol-related liver disease remains one of the leading causes worldwide. But it isn't the only cause, and as recent epidemiological data show, it isn't even always the dominant one anymore. This article explains the full picture of cirrhosis causes, the key distinction between its compensated and decompensated forms, and symptoms that require an urgent response.

This article is educational in nature

This text is informational and doesn't replace diagnosis or treatment provided by a hepatologist or gastroenterologist. Liver cirrhosis, regardless of its cause, requires ongoing specialist medical care — regular monitoring, not a one-time diagnosis.

The scale of the problem worldwide

Liver cirrhosis in 2021: Global Burden of Disease study

Strong evidence

Global Burden of Disease (GBD) 2021 research collaborators · PLOS ONE · 2025

Analysis of data from the global Global Burden of Disease study shows that the number of new liver cirrhosis cases worldwide rose from 36.9 million in 1990 to 58.4 million in 2021, while the total number of people living with cirrhosis (prevalence) rose from 988 million to 1.7 billion over the same period. Deaths from cirrhosis rose from 1.02 million in 1990 to 1.43 million in 2021, though the age-standardized mortality rate fell from 24.4 to 16.6 per 100,000 — indicating that the rise in absolute case numbers is driven mainly by population aging and growth rather than worsening per-capita medical care. Nonalcoholic fatty liver disease (NAFLD/MASLD) became the leading cause of new cirrhosis cases worldwide in 2021, with 48.3 million new cases (up from 24.8 million in 1990), overtaking both hepatitis B and hepatitis C.

View study

This shift in the underlying causes has practical implications: while the number of hepatitis-B-related cirrhosis cases keeps falling steadily (thanks partly to vaccination and antiviral drugs), cirrhosis linked to nonalcoholic fatty liver disease is rising in step with the global obesity and type 2 diabetes epidemic — a phenomenon we cover in more detail in a separate article on nonalcoholic fatty liver disease (NAFLD/MASLD).

The main causes of liver cirrhosis

The most common causes of liver cirrhosis

  • Nonalcoholic fatty liver disease (NAFLD/MASLD) and its advanced inflammatory form (NASH/MASH) — now the leading cause of new cirrhosis cases worldwide
  • Alcohol-related liver disease — chronic, excessive alcohol consumption leading to steatosis, inflammation, and ultimately liver fibrosis
  • Chronic hepatitis B and C — still a significant cause globally, though declining thanks to vaccination (hepatitis B) and effective antiviral drugs (hepatitis C)
  • Autoimmune liver diseases — autoimmune hepatitis, primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC)
  • Genetically determined metabolic diseases — hemochromatosis (excess iron accumulation) and Wilson's disease (excess copper accumulation)
  • Chronic right-sided heart failure and biliary tract diseases leading to chronic congestion and secondary liver damage
Myth

Liver cirrhosis is a disease that only affects people who misuse alcohol.

Fact

Alcohol-related liver disease is one of several leading causes of cirrhosis, but Global Burden of Disease data show that nonalcoholic fatty liver disease has now become the leading cause of new cases worldwide. Someone who has never drunk alcohol in excess can develop cirrhosis from obesity, diabetes, chronic viral hepatitis, an autoimmune condition, or a genetic disorder — this distinction matters, because automatically associating cirrhosis solely with alcohol sometimes delays diagnosis in patients without that particular risk factor.

Compensated cirrhosis — an insidious, silent stage

In the early stage, known as compensated cirrhosis, the liver — despite progressive fibrosis — is still able to carry out most of its functions at a level sufficient to maintain the body's homeostasis. This is exactly what makes this stage insidious: the absence of obvious symptoms means diagnosis is often delayed, and the disease is frequently discovered incidentally, during blood tests or imaging done for an entirely different reason.

Even at this stage, nonspecific symptoms can appear — chronic fatigue, weakness, or discomfort under the right ribs — but they're general enough to be easily attributed to other, less serious causes. That's why regular check-ups in people with known risk factors — rather than waiting for obvious symptoms to appear — are key to early detection.

Decompensation — a turning point in disease course

Decompensation radically changes the prognosis

The transition from compensated to decompensated cirrhosis occurs when the liver can no longer compensate for progressive damage, and serious complications appear: ascites (fluid accumulation in the abdominal cavity), bleeding from esophageal varices (dilated veins caused by portal hypertension), jaundice, or hepatic encephalopathy (impaired brain function due to the liver's inability to clear toxins from the blood). Decompensation occurs in some patients with compensated cirrhosis at a rate of 4–12% per year and marks a turning point — from that point on, Global Burden of Disease data show mortality risk rising nearly tenfold compared to the compensated stage.

Main complications of decompensated cirrhosis

  • Ascites — fluid accumulation in the abdominal cavity, leading to increased abdominal girth and discomfort
  • Bleeding from esophageal or gastric varices — a potentially life-threatening complication of portal hypertension
  • Hepatic encephalopathy — ranging from mild concentration and sleep disturbances to deep confusion and coma
  • Jaundice — yellowing of the skin and the whites of the eyes resulting from the liver's inability to properly metabolize bilirubin
  • Increased risk of infections, including spontaneous bacterial peritonitis
  • Increased risk of developing hepatocellular carcinoma, requiring regular imaging surveillance

Check your profile

Not sure which supplements actually make sense for you?

Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.

Takes about 2 minutesBased on scientific evidence

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

Why early diagnosis changes the prognosis

Cirrhosis itself — the permanent replacement of liver tissue with scar tissue — isn't a fully reversible process, but early detection of the underlying disease and consistently treating its cause can significantly slow fibrosis progression and, for some patients, prevent or delay decompensation. This is especially true for causes that can genuinely be influenced: weight loss for cirrhosis related to NAFLD/MASLD, complete abstinence for alcohol-related disease, antiviral treatment for hepatitis B and C, or immunosuppressive therapy for autoimmune diseases.

This distinction — between the irreversibility of the scar tissue itself and the ability to halt further disease progression — is key to a realistic understanding of what to expect from treatment. The therapeutic goal in a patient diagnosed with cirrhosis is rarely to 'reverse' the disease back to a healthy liver, and almost always to halt or maximally slow further damage and prevent complications.

Symptoms requiring urgent medical consultation

When to see a doctor urgently

The following symptoms require prompt medical evaluation, regardless of whether any liver disease has previously been diagnosed: yellow discoloration of the skin or the whites of the eyes, sudden increase in abdominal girth or leg swelling, vomiting blood or material resembling coffee grounds, tarry, black stools (possible gastrointestinal bleeding), confusion, daytime drowsiness or difficulty concentrating unexplained by another cause, easy bruising or bleeding gums, and chronic, unexplained fatigue that persists despite rest. Any of these symptoms, especially in someone with risk factors (obesity, diabetes, chronic viral hepatitis, a history of alcohol misuse), requires prompt diagnostic workup rather than 'wait and see.'

Summary table

QuestionShort answer
Does cirrhosis always result from alcohol?No — NAFLD/MASLD has become the leading global cause, alongside viral hepatitis and autoimmune diseases
What's the difference between compensated and decompensated cirrhosis?Compensated usually has no symptoms; decompensated involves complications like ascites, jaundice, or bleeding
How often does decompensation occur?In 4–12% of patients with compensated cirrhosis per year, according to Global Burden of Disease data
Is cirrhosis reversible?The scar tissue itself usually isn't, but treating the underlying cause can halt or slow further progression
When to see a doctor urgently?Jaundice, ascites, blood in vomit or stool, confusion, easy bruising

Liver cirrhosis — key facts at a glance

Our editorial recommendation

Liver cirrhosis is still too often seen as a disease with one cause and one type of patient — but global epidemiological data show a far more complex picture, in which nonalcoholic fatty liver disease has now moved into first place among causes. This changes how prevention should be approached: weight control, managing diabetes, and regular liver tests are becoming just as important a part of preventing cirrhosis as limiting alcohol consumption.

The distinction between compensated and decompensated stages is key — not because one of them 'doesn't need attention,' but because understanding this distinction helps explain why regular monitoring in people with risk factors makes sense well before obvious symptoms appear, rather than only after the first serious complication occurs.

Liver cirrhosis rarely begins with dramatic symptoms — it begins quietly, years earlier, with risk factors that can be identified and genuinely modified. That's the best moment to act, not the first episode of bleeding from esophageal varices.

Michał Nowak, VitMode editorial team

Frequently asked questions

No. Alcohol-related liver disease is one of the leading causes, but Global Burden of Disease study data show that nonalcoholic fatty liver disease (NAFLD/MASLD) has now become the leading cause of new cirrhosis cases worldwide. Other important causes include chronic hepatitis B and C, autoimmune diseases, and genetically determined metabolic disorders like hemochromatosis.

Compensated cirrhosis usually causes no obvious symptoms, because the liver, despite fibrosis, still performs its basic functions. Decompensated cirrhosis involves serious complications — ascites, jaundice, bleeding from esophageal varices, or hepatic encephalopathy — and carries a significantly worse prognosis.

According to published data, decompensation occurs in about 4–12% of patients with compensated cirrhosis per year. The rate depends on the cause of cirrhosis, how effectively the underlying disease is treated, and the presence of additional risk factors.

The scar tissue (fibrosis) itself in advanced cirrhosis usually doesn't fully regress, but early detection and effective treatment of the underlying disease — such as weight loss for NAFLD/MASLD, abstinence for alcohol-related disease, or antiviral treatment for hepatitis C — can significantly slow or halt further disease progression and reduce the risk of decompensation.

Noninvasive tools are most commonly used, such as the FIB-4 index calculated from routine blood tests and liver elastography (measuring liver stiffness), which allow the degree of fibrosis to be estimated without a biopsy in most patients. We cover this diagnostic process in more detail in our article on nonalcoholic fatty liver disease.

No — compensated cirrhosis is often asymptomatic or presents with very nonspecific symptoms, like chronic fatigue. This is one reason the disease is often diagnosed incidentally, during tests done for another reason, rather than based on obvious bodily signals.

Jaundice, a sudden increase in abdominal girth, vomiting blood, black tarry stools, confusion or excessive daytime drowsiness, and easy bruising are symptoms that require urgent medical consultation, as they may indicate cirrhosis decompensation.

Yes, and this applies regardless of the underlying cause of the disease. Maintaining a healthy body weight, managing diabetes and lipid disorders, complete abstinence from alcohol (regardless of the cause of cirrhosis), and following treatment recommendations for the underlying disease are key to slowing disease progression and delaying decompensation.

Sources

MN

Michał Nowak

MSc in Clinical Dietetics, certified sports-nutrition coach

Michał started out as a long-distance runner, before an injury forced him to rethink his career. Looking for a faster way back into shape, he discovered sports nutrition and never left — fascinated by the gap between the research and what "everyone knows" at the gym. He completed a degree in clinical dietetics, earned a sports-nutrition coaching certification, and ran his own practice for several years before joining VitMode. His writing keeps returning to one theme: a supplement won't replace the basics, but the right one, at the right time, makes a real difference — and that's the difference he tries to describe precisely, with citations instead of slogans. He still runs, though these days, as he puts it, purely for the fun of it.

Related articles

Lekarka wykonująca badanie USG w nowoczesnej klinice

TRT and the Liver — Does Injectable Testosterone Actually Damage It?

"Testosterone destroys your liver" is one of the most repeated warnings about TRT — and one of the least accurate. We explain where the fear comes from, why the route of administration is absolutely decisive here, and what the research on injections, gel, and pills actually shows.

13 min

August 20, 2026

Osoba trzymająca się za brzuch z powodu bólu

Ursodeoxycholic Acid (UDCA) and Preventing Gallstones After Rapid Weight Loss

Rapid, large weight loss — typical after bariatric surgery or very restrictive low-calorie diets — significantly raises the risk of gallstone formation. A randomized controlled trial tested whether prophylactic ursodeoxycholic acid (UDCA) after bariatric surgery reduces that risk, and found a very large effect. This is not, however, advice about ordinary, gradual weight loss — we discuss exactly who these results apply to, and who they don't.

11 min

August 27, 2026

Śniadanie z jajkiem i awokado, źródłem choliny

Choline and Nonalcoholic Fatty Liver Disease (NAFLD): What Does the Framingham Heart Study Show?

Choline is essential for transporting fat out of the liver, and its deficiency has been shown experimentally to cause fatty liver in humans within weeks. A new analysis of Framingham Heart Study data, covering more than 1,400 people followed for six years, shows that higher choline intake is associated with lower risk of developing nonalcoholic fatty liver disease (NAFLD) — with one important caveat regarding eggs as a choline source.

12 min

September 2, 2026

Anatomiczny model tułowia z widocznymi narządami wewnętrznymi

Vitamin E and Nonalcoholic Steatohepatitis: What the PIVENS Trial Found

Nonalcoholic steatohepatitis (NASH) is one of the few serious liver diseases that for decades lacked any approved pharmacological treatment. The large, multicenter PIVENS trial, published in the New England Journal of Medicine, showed that a high dose of vitamin E significantly improves liver histology in adults without diabetes — but with important caveats that are rarely discussed as loudly.

12 min

September 2, 2026

Related knowledge base entries

Comments (2)

  • KW

    Kasia W. 2 weeks ago

    Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.

  • MT

    Marek T. a month ago

    Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.